Colorectal neoplasia is the second most common cancer in the United States and other Western
countries with about 140,000 newly diagnosed cases per year in the United States with a
mortality rate of about 40%. The identification of a specific natural or synthetic compound
with the ability to reverse or suppress the process of colon carcinogenesis would have
profound implication in the development of colorectal adenomas and their subsequent
transformation to colon cancer. Furthermore, the establishment of a correlative
relationship between biomarkers of cell proliferation, differentiation, apoptosis and
adenoma recurrence would provide pivotal data required to elucidate cell signaling
mechanisms in future colon cancer chemoprevention trials.
Asymptomatic individuals from the age of 18 -80 years, undergoing clinically indicated
colonoscopy for colon polyps noted on screening flexible sigmoidoscopy or as routine
surveillance for a history of colon polyps, who are found to have at least one adenoma >
0.5cm will be eligible for entry.